ThruFlo Secures Funding to Advance Development of Its Flow Diverter for Bifurcation Aneurysms

June 16, 2026—ThruFlo Endovascular, Inc., a neuroendovascular medical device company, announced the completion of seed funding to accelerate development of its bifurcated flow diverter platform.

According to the company, the proceeds will be used to establish formal research and development operations, complete device design, initiate additional preclinical studies, and submit an investigational device exemption application to the FDA for the flow diverter.

ThruFlo stated that the device features an anatomically specific, dual-limb Y-shaped design that deploys as a single modality, eliminating the need for coiling and reducing procedural complexity, time, and risk.

“Today’s interventionalists are using sidewall off-label devices such as stents with multiple detachable coils or intrasaccular devices for treatment of bifurcation aneurysms, because there is simply nothing better available,” said Samuel M. Shaolian, CEO of ThruFlo Endovascular.

Shaolian continued, “Our device was designed from the ground up for this indication. Preclinical studies confirmed successful deployment and 2-month device patency, and we are focused on building the evidence that translates into better outcomes for patients.”

As noted in the press release, ThruFlo Endovascular is supported by a scientific advisory board that includes leading neurological surgeons and interventional neuroradiologists from Keck School of Medicine of USC in Los Angeles, California.

The company further stated that the seed funding was led by Atlas MedInnovation, which is based in Irvine, California.